Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Appointed director
CC transcript
NPS PHARMACEUTICALS INC (NPSP) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/10/2014 8-K Quarterly results
Docs: "NPS Pharma Reports Third-Quarter 2014 Financial Results Net global Gattex®/Revestive® sales of $28 million representing sequential growth of 28 percent Company on track to meet full-year financial guidance"
08/06/2014 8-K Quarterly results
Docs: "NPS Pharma Reports Second-Quarter 2014 Financial Results Net global Gattex®/Revestive® sales of $22 million representing sequential growth of 22 percent Full-year sales on track to meet guidance of $100 to $110 million"
05/08/2014 8-K Quarterly results
Docs: "NPS Pharma Reports First-Quarter 2014 Financial Results Net global Gattex®/Revestive® sales of $18 million representing 17 percent sequential growth"
02/18/2014 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014"
11/06/2013 8-K Form 8-K - Current report
08/08/2013 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Second Quarter 2013 Financial Results and Provides Business Update"
05/09/2013 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports First Quarter 2013 Financial Results"
02/21/2013 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports 2012 Financial Results and 2013 Guidance"
11/09/2012 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Third Quarter 2012 Financial Results and Reiterates Year-end Cash Guidance -- FDA Advisory Committee unanimously recommends approval of Gattex® for adult patients with short bowel syndrome -- -- One out of seven patients has now achieved independence from PN/IV fluids in ongoing STEPS 2 study -- -- Conference call today at 8:30 AM ET --"
08/01/2012 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Second Quarter 2012 Financial Results"
05/03/2012 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports First Quarter 2012 Financial Results -- Four additional patients weaned off parental nutrition and IV fluids while receiving Gattex therapy in ongoing STEPS 2 open-label extension study -- -- Results of Phase 3 REPLACE registration study of Natpara ® accepted for oral presentation at the annual meeting of The Endocrine Society in June -- -- Conference call today at 5:00 PM ET --"
11/03/2011 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Third Quarter 2011 Financial Results and Improves Cash Burn Guidance"
08/02/2011 8-K Form 8-K - Current report
05/03/2011 8-K Form 8-K - Current report
02/15/2011 8-K Form 8-K - Current report
11/02/2010 8-K Form 8-K - Current report
08/04/2010 8-K Form 8-K - Current report
05/05/2010 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports First Quarter 2010 Financial Results and Continued Progress of Two Phase 3 Registration Programs More than $90 million generated in 2010 from financing activities Conference call today at 5:00 PM ET"
03/11/2010 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports 2009 Results and 2010 Outlook"
11/04/2009 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash Burn Guidance -- Conference call today at 5:00 PM ET --"
08/06/2009 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Second Quarter 2009 Financial Results; Two Phase 3 Registration Programs Continue to Advance on Stated Timelines -- Conference call today at 9:00 AM ET --"
05/05/2009 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports First Quarter 2009 Financial Results; Registration Studies Advance for Lead Product Candidates Conference call today at 8:30 AM ET"
03/13/2009 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Strong 2008 Results; Phase 3 Registration Studies Underway for Two Product Candidates Conference call today at 8:30 AM ET"
11/05/2008 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update —Management Improves 2008 Cash Burn Guidance — —IRB Approval Process Underway for Two Registration Studies— — Conference Call Today at 8:00 AM ET"
08/07/2008 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Second Quarter Financial Results"
05/07/2008 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports First Quarter 2008 Financial Results and Business Update"
03/13/2008 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports 2007 Financial Results Conference call scheduled for 5:00 pm ET today"
11/01/2007 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance"
08/07/2007 8-K Quarterly results
Docs: "NPS Pharmaceuticals Raises $200 Million to Retire Debt, Reports Second Quarter Financial Results and Revises Guidance",
"NPS Completes $100 Million Series B Note Offering Backed by Sensipar Royalties Proceeds to Be Used to Retire 3% Notes Due 2008",
"Proceeds to Be Used to Retire 3% Convertible Debt Notes Due June 2008"
05/09/2007 8-K Quarterly results
Docs: "NPS Reports First Quarter 2007 Financial Results and Progress in Executing New Business Plan, Reiterates Guidance"
03/14/2007 8-K Quarterly results
Docs: "NPS PHARMACEUTICALS REPORTS 2006 RESULTS AND PROGRESS, ANNOUNCES NEW BUSINESS PLAN TO ADVANCE PIPELINE Company to Focus on Late-Stage Products and Explore New Indications, Cut Costs, Outsource Development Work, Consolidate Operations in New Jersey Conference Call/Webcast Scheduled for 3 pm Eastern Time Today"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy